Paul SekhriPaul Sekhri is the President and Chief Executive Officer of Cerimon Pharmaceuticals. Prior to founding Cerimon, Mr. Sekhri was President and Chief Business Officer of ARIAD Pharmaceuticals, Inc., a Nasdaq-listed oncology company based in Cambridge, MA. In 2002 Mr. Sekhri joined the Sprout Group, the venture affiliate of Credit Suisse First Boston in New York, where he was a Partner for healthcare technology investments. Prior to joining Sprout, Mr. Sekhri spent four years at Novartis, most recently as Senior Vice President and Head of Global Search and Evaluation, Business Development and Licensing for Novartis Pharma AG. At Novartis, he was responsible for the creation of Novartis Pharmaceuticals’ Disease Area Strategy, as well as establishing a dedicated function focused on the identification and evaluation of new opportunities for the company. Prior to this, Mr. Sekhri set up a new department, Early Commercial Development, in order to ensure the differential competitive advantage of Novartis’ pipeline. Mr. Sekhri completed graduate work in neuroscience at the University of Maryland School of Medicine where he also received his BS in Zoology.Mr. Sekhri is currently a member of the Board of Directors for Biodel Inc., based in Danbury, CT, and ARYx Therapeutics, a San Francisco-based pharmaceutical company where he also serves as chairman of the compensation committee. In addition, he is a member of the Advisory Board for The BioExec Institute, Inc., in Cambridge, MA. Mr. Sekhri also serves on the Board of Directors of the Irvington Institute for Immunological Research, a non-profit world leader in the funding of basic research in immunology. He is a Senior Advisor to Preferred Time, Inc. and an Advisor to the International Health Organization. |
|
